Literature DB >> 17704515

Macrolide-resistant Campylobacter: the meat of the matter.

Aimee E Belanger1, Thomas R Shryock.   

Abstract

The use of macrolide antibiotics in food animals has the potential to select for macrolide-resistant strains of resident bacterial flora. This may include the animal pathogens that are the intended targets of macrolide antibiotic intervention and Campylobacter, common inhabitants of the intestinal tract of food animals that are zoonotic pathogens in man. Such Campylobacter strains are not only resistant to the macrolide antibiotics used in food animals, e.g. tylosin, tilmicosin and tulathromycin, but to the macrolide antibiotics used in human medicine, e.g. erythromycin, azithromycin and clarithromycin, as well. Retail meat is a possible source of Campylobacter and persons consuming the meat derived from macrolide-treated food animals could acquire infections due to macrolide-resistant strains of this organism. Erythromycin is sometimes used to treat human cases of campylobacteriosis and those infected with animal-derived macrolide-resistant Campylobacter may not respond to treatment. The actual risk to human health from the use of macrolide antibiotics in food animals has been difficult to determine because of a lack of information about the macrolide-resistant Campylobacter found on the farm and in the clinic. Recently, however, a plethora of new information has become available on this topic. This review discusses what is currently known about the selection of macrolide-resistant Campylobacter in food animals, the prevalence of macrolide-resistant Campylobacter on retail meat, the prevalence of animal-derived macrolide-resistant Campylobacter in the clinic and the human health consequences associated with macrolide-resistant Campylobacter infection. This work will emphasize the comprehensive body of data generated in Denmark and the US as part of government-sponsored research studies over the last 10 years. These scientific findings may allow informed decisions to be made in the future about how macrolide antibiotics should be used in food animals while still safeguarding human health.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17704515     DOI: 10.1093/jac/dkm300

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  11 in total

1.  Epidemiological relationships of Campylobacter jejuni strains isolated from humans and chickens in South Korea.

Authors:  Jae-Young Oh; Yong-Kuk Kwon; Bai Wei; Hyung-Kwan Jang; Suk-Kyung Lim; Cheon-Hyeon Kim; Suk-Chan Jung; Min-Su Kang
Journal:  J Microbiol       Date:  2016-12-30       Impact factor: 3.422

2.  Constitutive and Inducible Expression of the rRNA Methylase Gene erm(B) in Campylobacter.

Authors:  Fengru Deng; Jianzhong Shen; Maojun Zhang; Congming Wu; Qijing Zhang; Yang Wang
Journal:  Antimicrob Agents Chemother       Date:  2015-08-10       Impact factor: 5.191

Review 3.  Antibiotic resistance in Campylobacter: emergence, transmission and persistence.

Authors:  Taradon Luangtongkum; Byeonghwa Jeon; Jing Han; Paul Plummer; Catherine M Logue; Qijing Zhang
Journal:  Future Microbiol       Date:  2009-03       Impact factor: 3.165

4.  Antimicrobial susceptibilities of multidrug-resistant Campylobacter jejuni and C. coli strains: in vitro activities of 20 antimicrobial agents.

Authors:  Mirva Lehtopolku; Ulla-Maija Nakari; Pirkko Kotilainen; Pentti Huovinen; Anja Siitonen; Antti J Hakanen
Journal:  Antimicrob Agents Chemother       Date:  2009-12-28       Impact factor: 5.191

5.  Campylobacter antimicrobial resistance in Peru: a ten-year observational study.

Authors:  Simon Pollett; Claudio Rocha; Rito Zerpa; Lilian Patiño; Augusto Valencia; Máximo Camiña; José Guevara; Martha Lopez; Nancy Chuquiray; Eduardo Salazar-Lindo; Carlos Calampa; Martín Casapia; Rina Meza; Maruja Bernal; Drake Tilley; Michael Gregory; Ryan Maves; Eric Hall; Franca Jones; C Sofia Arriola; Marieke Rosenbaum; Juan Perez; Matthew Kasper
Journal:  BMC Infect Dis       Date:  2012-08-16       Impact factor: 3.090

6.  Identification and antimicrobial resistance of campylobacter species isolated from animal sources.

Authors:  Ioanna Marinou; Sotiris Bersimis; Anastassios Ioannidis; Chryssoula Nicolaou; Angeliki Mitroussia-Ziouva; Nicholaos John Legakis; Stylianos Chatzipanagiotou
Journal:  Front Microbiol       Date:  2012-02-24       Impact factor: 5.640

7.  Antimicrobial susceptibility of Campylobacter jejuni and Campylobacter coli: comparison between Etest and a broth dilution method.

Authors:  Maya Azrad; Linda Tkhawkho; Natalia Isakovich; Orna Nitzan; Avi Peretz
Journal:  Ann Clin Microbiol Antimicrob       Date:  2018-05-23       Impact factor: 3.944

8.  Campylobacter jejuni bacteremia in a patient with asplenia and enteritis.

Authors:  Ramírez Isabel
Journal:  IDCases       Date:  2019-05-09

9.  Effects of low concentrations of erythromycin, penicillin, and virginiamycin on bacterial resistance development in vitro.

Authors:  Beilei Ge; Kelly J Domesle; Qianru Yang; Shenia R Young; Crystal L Rice-Trujillo; Sonya M Bodeis Jones; Stuart A Gaines; Marla W Keller; Xin Li; Silvia A Piñeiro; Brooke M Whitney; Heather C Harbottle; Jeffrey M Gilbert
Journal:  Sci Rep       Date:  2017-09-08       Impact factor: 4.379

10.  Genetic Basis and Clonal Population Structure of Antibiotic Resistance in Campylobacter jejuni Isolated From Broiler Carcasses in Belgium.

Authors:  Mohamed Elhadidy; William G Miller; Hector Arguello; Avelino Álvarez-Ordóñez; Alexandra Duarte; Katelijne Dierick; Nadine Botteldoorn
Journal:  Front Microbiol       Date:  2018-05-17       Impact factor: 5.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.